City of Hope and Biopharmaceutical Research Company announce first patient has received BRC-001, a first-in-class cannabinoid therapeutic, in a clinical trial investigating supportive care in breast cancer

On September 12, 2024 City of Hope, one of the largest cancer research and treatment organizations in the United States, and Biopharmaceutical Research Company (BRC), a specialty pharmaceutical company developing proprietary cannabinoid therapeutics, reported that the first patient has received BRC-001, an experimental supportive care therapy for breast cancer patients (Press release, City of Hope, SEP 12, 2024, View Source [SID1234646543]). City of Hope researchers are evaluating whether this cannabinoid therapeutic candidate could address joint pain (arthralgia) that is often a side effect of aromatase inhibitors, a type of hormone therapy used to treat postmenopausal women with breast cancer.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Aromatase inhibitors such as letrozole, anastrozole or exemestane are prescribed as standard of care for postmenopausal women with estrogen-receptor positive breast cancer to decrease breast cancer recurrence and mortality. About half of patients who take aromatase inhibitors experience joint pain, and many of these patients report severe symptoms. A significant number of patients discontinue cancer treatment due to this side effect. Currently, there is no approved treatment for aromatase inhibitor-induced arthralgia (AIIA). Patients often use over-the-counter, anti-inflammatory medications and other treatment options with limited efficacy for short-term pain management.

"Cannabis-derived therapeutics are one of the most promising treatments to address underserved pain conditions. BRC has developed a proprietary therapy with unique properties to address joint pain in breast cancer patients taking aromatase inhibitors. We look forward to providing a therapy for these patients that allows them to complete a full course of treatment," said George Hodgin, CEO and founder of BRC, the industry leader in federally compliant cannabinoid therapeutics development.

"This research to alleviate or eliminate side effects, such as joint pain, is part of City of Hope’s commitment to provide compassionate, individualized care," said Lisa Yee, M.D., City of Hope professor of breast surgery and lead investigator of the trial. "We hope this work will yield innovative, FDA-approved therapies to help patients complete their lifesaving treatments."

The clinical trial entitled "High Cannabidiol (CBD) Standardized Extract for Aromatase Inhibitor-Induced Arthralgia – A randomized controlled double blind clinical trial" is a randomized, placebo-controlled study at City of Hope’s Los Angeles cancer center. It is designed to assess the safety, tolerability and efficacy of a botanically derived proprietary formulation developed by BRC (BRC-001) when taken orally to address the symptoms of AIIA.

Yuman Fong, M.D., Sangiacomo Family Chair in Surgical Oncology at City of Hope, added, "Cannabis-derived medicines hold promise in alleviating symptoms of cancer and cancer therapy. They are potentially alternatives to opiates for pain relief, and alternatives to benzodiazepines for relief of anxiety and insomnia. We look forward to working with BRC in conducting trials to bring these medicines forward to help patients suffering from cancer."

Epitopea Awarded Grant from Innovate UK’s Cancer Therapeutics Programme

On September 12, 2024 Epitopea, a transatlantic cancer immunotherapeutics company developing accessible off-the-shelf RNA-based immunotherapies, reported it has been awarded a grant of just over £500,000 (approximately $658,000 USD) from Innovate UK (Press release, Epitopea, SEP 12, 2024, View Source [SID1234646527]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Epitopea was selected to receive funding from Innovate UK’s £12 million Cancer Therapeutics programme (1), which will provide a non-dilutive grant in support of research that is aimed at developing both therapeutic vaccines and T cell receptor-based therapies targeting antigens that are differentially presented by stromal cells. This class of therapies has the potential to impact patient outcomes given the well-established role of stromal cells in thwarting a therapeutic response to many established therapies.

The antigens in question were discovered by Epitopea’s CryptoMapTM platform, which enables targeting of a new class of untapped tumor specific antigens, known as CryptigenTM TSAs, that are broadly shared across multiple patients with the same tumor type. Epitopea intends to leverage these aberrantly expressed CryptigenTM TSAs to expand its therapeutic pipeline of RNA immunotherapies aimed at extending the durability of patient responses.

Dr. Jon Moore, Epitopea’s CSO, said:

"We believe better cancer therapies are needed to transform the lives of patients, especially in hard-to-treat solid tumors where overall survival can still be poor. Targeting stromal cells with immunotherapeutics represents an attractive and highly differentiated approach that we believe may translate into a deeper, more durable therapeutic response. We are therefore delighted that we have secured this grant support from Innovate UK’s Cancer Therapeutics programme, in recognition of our work developing life-changing cancer therapeutics."

Dr Karen Spink, Head of Medicines at Innovate UK, said:

"We are excited to see the diversity of businesses that have been supported through our Cancer Therapeutics programme. The industry-led R&D projects will advance transformative treatments for a range of cancers. This portfolio of investments will diversify the pipeline of targeted, safe, and effective therapies for cancer patients."

TCBP Announces First Patient Completed the Full Dose Regimen in ACHIEVE Clinical Trial

On September 12, 2024 TC BioPharm (Holdings) PLC ("TC BioPharm" or the "Company") (NASDAQ: TCBP) a clinical stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer and other indications, reported the first patient has completed the full dose regimen in the ACHIEVE Phase 2b trial ongoing in the UK with no drug related Adverse Events seen in any of the re start patients (Press release, TC Biopharm, SEP 12, 2024, https://www.prnewswire.com/news-releases/tcbp-announces-first-patient-completed-the-full-fose-regimen-in-achieve-clinical-trial-302246114.html [SID1234646544]). As previously stated, patients are eligible to receive up to 4 total doses of TCB under the ACHIEVE protocol. Based on the amended dosing, this patient received approximately one billion cells in the TCB008 dosing regimen.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

One patient in Cohort A has successfully completed the full dosing regimen having received all 4 doses. Preliminary safety data indicate the 5mL dose of TCB008 is well tolerated, with no TCB008-related Adverse Events. These data outputs are indicative of TCB008’s safety profile, in support of the ACHIEVE study safety objectives and endpoints. New patients will continue to be identified, screened, and enrolled into the study.

It’s expected that a further three patients will have received their 4th and final dose by the end of September. 14 patients in Cohort A are initially expected to receive TCB008 and, pending confirmation of primary endpoints, a further 10 patients will be recruited into the cohort for a total of 24 patients.

"We are extremely pleased to announce that the full dosing regimen is completed by the first patient to receive the increased dose of TCB008 under the ACHIEVE trial. Including the fully-dosed first patient in the ACHIEVE Phase 2b trial, we have observed no drug related Adverse Events in any of the restart patients," said Bryan Kobel, Chief Executive Officer of TC BioPharm. "This initial feedback speaks to the safety and tolerability of TCBP’s drug. An additional three patients will receive their 4th and final dose by the end of September. While we are able to see safety and tolerability in the immediate aftermath of dosing for ACHIEVE to update investors, the measurement for efficacy and the release of that data will be after completion of the cohort and the data clean per regulatory mandate. We are seeing strong recruitment and enrollment at our active sites and expect to be able to announce a full data set in the first half of 2025 inclusive of primary and secondary endpoints"

The ACHIEVE UK clinical trial is an open-label, phase II study designed to evaluate the efficacy and effectiveness of TCB008 in patients with AML or MDS/AML, with either refractory or relapsed disease.

Kintara Therapeutics Provides Update on Corporate Developments and REM-001 Clinical Study

On September 11, 2024 Kintara Therapeutics, Inc. (Nasdaq: KTRA) ("Kintara"), a biopharmaceutical company focused on the development of new solid tumor cancer therapies, reported a corporate and REM-001 clinical study update (Press release, Kintara Therapeutics, SEP 11, 2024, View Source [SID1234646511]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Corporate Updates

In April 2024, Kintara and TuHURA Biosciences, Inc. ("TuHURA") entered into definitive merger agreement (the "Merger Agreement"), pursuant to which Kayak Mergeco, Inc., Kintara’s wholly-owned subsidiary, will merge with and into TuHURA, with TuHURA surviving the merger and becoming Kintara’s direct, wholly-owned subsidiary (the "Merger").

Kintara’s existing stockholders will own approximately 5.45% of combined company’s common stock at the closing of the proposed Merger on a pro forma fully diluted basis, inclusive of the contingent value rights ("CVRs") to receive shares of common stock of the combined company upon the achievement of enrollment of a minimum of 10 patients in the REM-001 study with such patients each completing 8 weeks of follow-up on or before December 31, 2025 (the "Milestone").

Special Meeting of Stockholders (the "Special Meeting") to obtain stockholder approval of the proposals set forth in Kintara’s proxy statement for the Special Meeting required to allow for completion of the proposed Merger with TuHURA will be held virtually on Friday, September 20, 2024, at 9:00 a.m., Eastern Time via live audio webcast. In order to attend, register in advance at www.viewproxy.com/kintarasm/2024 by 11:59 p.m., Eastern Time, on September 19, 2024. Kintara stockholders of record on August 14, 2024 (the "Record Date") are eligible to vote even if not a stockholder after the Record Date.

Stockholders immediately prior to the closing of the proposed Merger, even if not a stockholder on the Record Date, are eligible to receive CVRs, entitling such holders to receive shares of common stock of the combined company upon achievement of the Milestone.

Vote By Phone: Please call Alliance Advisors, Kintara’s proxy solicitor, toll-free, at (866) 619-8907, if in North America. International voters can call +1 (551) 210-9859. You can also contact Alliance Advisors if you have any questions about voting.

Vote By Internet: Vote at www.proxyvote.com using your control number by following the instructions shared by your broker, bank or other nominee.

If you are a Robinhood holder, proxy voting emails are sent by [email protected] and voting is hosted by Say Technologies. You will be able to vote and view materials directly from your email.
REM-001 Clinical Study Update

As of September 10, 2024, the REM-001 study in patients with cutaneous metastatic breast cancer (CMBC) has enrolled four of the 10 patients needed to reach the minimum patient enrollment to assess safety and appropriate Phase 3 dose with several other patients identified as study candidates at Kintara’s clinical sites, the Memorial Sloan Kettering Cancer Center and the Montefiore Medical Center, the University Hospital for Albert Einstein College of Medicine.

Consistent with REM-001’s safety profile, no treatment-related safety issues have been identified to-date, and assessment of the appropriate Phase 3 dose is ongoing.

CMBC represents an unmet medical need, as there currently are no approved or effective therapies. REM-001 may potentially offer these patients a much needed treatment option. The majority of the cost associated with the REM-001 study is being covered by a $2.0 million Small Business Innovation Research (SBIR) grant Kintara was awarded previously from the National Institutes of Health.
Without the completion of the proposed Merger with TuHURA, Kintara may not have adequate financial resources to continue the REM-001 study or operate its business and may be required to seek the protection of the bankruptcy courts. Kintara stockholders are urged to vote their shares before the Special Meeting on September 20, 2024.

Merck to Participate in the Bank of America 2024 Global Healthcare Conference

On September 11, 2024 Merck (NYSE: MRK), known as MSD outside of the United States and Canada, reported that Joseph Romanelli, president, Human Health International, is scheduled to participate in a fireside chat at the Bank of America 2024 Global Healthcare Conference on Wednesday, Sept. 18, 2024, at 6:40 a.m. EDT / 11:40 a.m. BST (Press release, Merck & Co, SEP 11, 2024, View Source [SID1234646512]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Investors, analysts, members of the media and the general public are invited to listen to a live audio webcast of the presentation at this weblink.